Background
Methods
Patients
Study oversight and design
Study endpoints and procedures
Statistical methods
Results
Study population
Characteristic | Fingolimod 0.5 mg (n = 47) | Fingolimod 1.25 mg (n = 46) | Placebo-fingolimod 0.5 mg (n = 27) | Placebo-fingolimod 1.25 mg (n = 23) |
---|---|---|---|---|
Patient demographic
| ||||
Age, years | ||||
Mean (SD) | 34.9 (9.0) | 35.7 (8.8) | 34.2 (9.1) | 35.5 (8.4) |
Median (range) | 34.0 (19–52) | 36.0 (18–55) | 34.0 (18–52) | 34.0 (21–51) |
Female, n (%) | 33 (70.2) | 31 (67.4) | 19 (70.4) | 14 (60.9) |
BMI, kg/m2
| ||||
Mean (SD) | 21.8 (3.2) | 22.0 (3.9) | 21.0 (2.6) | 20.7 (3.1) |
Median (range) | 21.5 (15.1–32.6) | 21.1 (18.1–36.2) | 20.8 (15.0–26.2) | 20.2 (13.8–28.8) |
Disease characteristic
| ||||
Clinical pattern of MS, n (%) | ||||
Relapsing-remitting | 44 (93.6) | 45 (97.8) | 27 (100.0) | 23 (100.0) |
Secondary progressive | 3 (6.4) | 1 (2.2) | 0 (0.0) | 0 (0.0) |
Duration of MS since first symptom, years | ||||
Mean (SD) | 8.2 (6.6) | 7.6 (5.5) | 8.4 (8.1) | 8.4 (7.2) |
Median (range) | 6.4 (1–26) | 6.2 (0–21) | 5.4 (1–27) | 5.9 (1–24) |
Number of relapses within previous year | ||||
Mean (SD) | 1.4 (0.9) | 1.5 (1.0) | 2.1 (2.1) | 1.4 (0.7) |
Median (range) | 1.0 (0–3) | 1.0 (0–4) | 2.0 (1–12) | 1.0 (0–3) |
Number of relapses within previous 2 years | ||||
Mean (SD) | 2.1 (1.3) | 2.2 (1.6) | 3.2 (4.0) | 2.5 (1.4) |
Median (range) | 2.0 (0–7) | 2.0 (0–6) | 2.0 (1–22) | 2.0 (0–5) |
EDSS score | ||||
Mean (SD) | 2.4 (1.9) | 1.9 (1.7) | 1.9 (1.6) | 2.4 (1.6) |
Median (range) | 2.0 (0.0–6.0) | 2.0 (0.0–6.0) | 1.5 (0.0–5.0) | 2.0 (0.0–5.5) |
MRI characteristics
| ||||
Patients free of Gd-enhancing lesions | ||||
n (%) | 28 (59.6) | 22 (47.8) | 13 (48.1) | 17 (73.9) |
Number of Gd-enhancing lesions | ||||
Mean (SD) | 1.0 (1.59) | 1.7 (2.42) | 1.7 (2.45) | 0.7 (1.49) |
Median (range) | 0.0 (0–5) | 1.0 (0–9) | 1.0 (0–9) | 0.0 (0–5) |
Number of T2 lesions | ||||
Mean | 30.3 (22.83) | 34.6 (24.15) | 28.9 (23.22) | 33.3 (23.11) |
Median (range) | 24.0 (4–100) | 29.5 (5–119) | 23.0 (3–98) | 35.0 (1–91) |
MS medication history
| ||||
Treatment-naïve patients, n (%) | 16 (34.0) | 21 (45.7) | 16 (59.3) | 8 (34.8) |
Previously treated patients, n (%) | 31 (66.0) | 25 (54.3) | 11 (40.7) | 15 (65.2) |
Any interferon beta | 30 (63.8) | 25 (54.3) | 10 (37.0) | 14 (60.9) |
Other MS medications | 9 (19.1) | 6 (13.0) | 2 (7.4) | 3 (13.0) |
Efficacy outcomes
MRI outcomes
Continuous fingolimod groups | Placebo to fingolimod switch groups | |||
---|---|---|---|---|
Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | |
MRI outcomes (MRI analysis population)
| n = 45 | n = 42 | n = 23 | n = 20 |
Patients free of Gd-enhancing lesions, n/totala (%) | ||||
Both months 3 and 6 | 35/45 (77.8) | 37/42 (88.1) | 6/23 (26.1) | 11/20 (55.0) |
Both months 9 and 12 | 38/45 (84.4) | 36/42 (85.7) | 16/23 (69.6) | 13/19 (68.4) |
Number of Gd-enhancing lesions | ||||
Month 6 | 0.1 (0.32) | 0.2 (1.08) | 1.3 (1.84) | 1.2 (1.96) |
Month 12 | 0.0 (0.15) | 0.0 (0.15) | 0.1 (0.31) | 0.2 (0.54) |
Patients free of new/newly enlarged T2 lesions, n/totala (%) | ||||
Months 0–6 | 30/45 (66.7) | 24/42 (57.1) | 5/23 (21.7) | 10/19 (52.6) |
Months 7–12 | 39/45 (86.7) | 37/42 (88.1) | 13/21 (61.9) | 11/17 (64.7) |
Number of new/newly enlarged T2 lesions | ||||
Months 0–6 | 0.9 (2.1) | 1.0 (2.0) | 7.7 (14.5) | 5.1 (6.8) |
Months 7–12 | 0.3 (1.1) | 0.2 (0.5) | 0.6 (1.2) | 0.5 (0.9) |
Clinical outcomes (clinical analysis population)
| n = 47 | n = 46 | n = 27 | n = 23 |
Patients free of relapse, nb (%) | ||||
Months 0–6 | 38 (80.9) | 38 (82.6) | 18 (66.7) | 14 (60.9) |
Months 7–12 | 42 (89.4) | 41 (89.1) | 24 (88.9) | 21 (91.3) |
Annualized relapse ratec
| ||||
Months 0–6 | 0.47 | 0.39 | 0.97 | 1.22 |
Months 7–12 | 0.23 | 0.28 | 0.26 | 0.21 |
EDSS score change from core baseline | ||||
Month 6 | 0.00 (0.36) | −0.21 (0.59) | 0.04 (1.00) | 0.26 (0.78) |
Month 12 | −0.02 (0.46) | −0.02 (0.83) | −0.32 (0.66) | −0.11 (0.95) |
Clinical outcomes
Safety and tolerability
Adverse event, n (%) | Placebo-fingolimod 0.5 mg (n = 27) | Placebo-fingolimod 1.25 mga(n = 23) | Continuous fingolimod 0.5 mg (n = 47) | Continuous fingolimod 1.25 mga(n = 46) |
---|---|---|---|---|
Any adverse event | 22 (81.5) | 23 (100) | 35 (74.5) | 41 (89.1) |
Any serious adverse event | 1 (3.7) | 4 (17.4) | 1 (2.1) | 0 (0.0) |
Any adverse event leading to discontinuation of study drug | 5 (18.5) | 3 (13.0) | 2 (4.3) | 0 (0.0) |
Any infection or infestation adverse event | 11 (40.7) | 14 (60.9) | 23 (48.9) | 28 (60.9) |
Most commonly reported adverse events
b
| ||||
Nasopharyngitis | 7 (25.9) | 7 (30.4) | 16 (34.0) | 19 (41.3) |
Liver function test abnormal | 4 (14.8) | 9 (39.1) | 3 (6.4) | 4 (8.7) |
Leukopenia | 4 (14.8) | 1 (4.3) | 0 (0.0) | 3 (6.5) |
Bradycardia | 0 (0.0) | 3 (13.0) | 0 (0.0) | 0 (0.0) |
Influenza | 0 (0.0) | 3 (13.0) | 0 (0.0) | 2 (4.3) |
Second-degree atrioventricular block | 0 (0.0) | 3 (13.0) | 0 (0.0) | 0 (0.0) |
Headache | 0 (0.0) | 2 (8.7) | 5 (10.6) | 0 (0.0) |
Lymphocyte count decreased | 1 (3.7) | 2 (8.7) | 1 (2.1) | 2 (4.3) |
Lymphopenia | 0 (0.0) | 2 (8.7) | 0 (0.0) | 3 (6.5) |
γ-glutamyltransferase increased | 1 (3.7) | 2 (8.7) | 1 (2.1) | 0 (0.0) |
White blood cell count decreased | 0 (0.0) | 2 (8.7) | 0 (0.0) | 1 (2.2) |
Eczema | 0 (0.0) | 1 (4.3) | 1 (2.1) | 4 (8.7) |
Rash | 2 (7.4) | 1 (4.3) | 1 (2.1) | 0 (0.0) |
Alanine aminotransferase increased | 2 (7.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Blood triglycerides increased | 2 (7.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Dental caries | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (6.5) |
Diarrhea | 1 (3.7) | 0 (0.0) | 2 (4.3) | 3 (6.5) |
Stomatitis | 1 (3.7) | 1 (4.3) | 0 (0.0) | 3 (6.5) |
Pharyngitis | 0 (0.0) | 1 (4.3) | 1 (2.1) | 3 (6.5) |
Tinea pedis | 1 (3.7) | 1 (4.3) | 3 (6.4) | 0 (0.0) |
Skin papilloma | 0 (0.0) | 0 (0.0) | 3 (6.4) | 0 (0.0) |
Serious adverse events
| ||||
Bradycardia | 0 (0.0) | 2 (8.7) | 0 (0.0) | 0 (0.0) |
Leukoencephalopathyc
| 0 (0.0) | 1 (4.3) | 0 (0.0) | 0 (0.0) |
Multiple sclerosis relapse | 0 (0.0) | 0 (0.0) | 1 (2.1) | 0 (0.0) |
Neuromyelitis optica | 1 (3.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Abortion induced | 0 (0.0) | 1 (4.3) | 0 (0.0) | 0 (0.0) |
Clinical courses and safety events in patients positive for anti-AQP4 antibodies
Patient | Treatment | Clinical course and safety events (onseta) |
---|---|---|
Continuous fingolimod
| ||
1 | Fingolimod 0.5 mg | Bradycardia (day 2); chest discomfort (day 2); enlargement of a pre-existing spinal cord lesion, LESCL, pons and midbrain lesions (day 9); myelitis and LESCL (day 145); diplopia, right upper limb paresis, multiple lesions in the cervical and thoracic cord, brainstem, cerebellum and cerebrum (day 235) |
2b
| Fingolimod 1.25 mg | Decreased heart rate (day 1); myelitis relapse (day 5); decreased heart rate (day 5; day 1 after drug interruption); abnormal liver function test result (day 85); asymptomatic multiple enhancing lesions in the bilateral cerebral white matter and an asymptomatic enhancing spinal cord lesion at C6 (6 days after fingolimod discontinuation); conduction and amnestic aphasia (3 weeks after fingolimod discontinuation) |
Switched from placebo to fingolimod
| ||
3 | Placebo/fingolimod 0.5 mg | Recurrence of right optic neuritis and myelitis (day 29 of extension phase); dysarthria, right ataxia and weakness, right frontal lobe lesion (3 months); right upper limb weakness (4 months); left parietal lobe lesion, left paresthesia, dizziness and eye movement disturbance (1 month after fingolimod discontinuation) |
4 | Placebo/fingolimod 1.25 mg | Relapse showing left hemispheric symptoms and exacerbation of cerebral and cerebellar white matter lesions (day 9 in the extension phase)c
|